Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | $1.58 | $1.58 | $1.58 |
Q2 2024 | 1 | $1.34 | $1.34 | $1.34 |
Q3 2024 | 1 | $1.54 | $1.54 | $1.54 |
Q4 2024 | 1 | -$0.15 | -$0.15 | -$0.15 |
Q1 2025 | 1 | -$0.17 | -$0.17 | -$0.17 |
Q2 2025 | 1 | -$0.15 | -$0.15 | -$0.15 |
Q3 2025 | 1 | -$0.12 | -$0.12 | -$0.12 |
Q1 2026 | 1 | -$0.09 | -$0.09 | -$0.09 |
Q2 2026 | 1 | -$0.12 | -$0.12 | -$0.12 |
Q3 2026 | 1 | -$0.08 | -$0.08 | -$0.08 |
Q4 2026 | 1 | -$0.09 | -$0.09 | -$0.09 |
Q1 2027 | 1 | -$0.09 | -$0.09 | -$0.09 |
Q2 2027 | 1 | -$0.03 | -$0.03 | -$0.03 |
Navidea Biopharmaceuticals, Inc. last posted its earnings results on Wednesday, August 11th, 2021. The company reported $-0.09 earnings per share for the quarter, missing analysts' consensus estimates of $-0.09 by $0. The company had revenue of 0 for the quarter and had revenue of 65,652 for the year. Navidea Biopharmaceuticals, Inc. has generated $-1 earnings per share over the last year ($-0.56 diluted earnings per share) and currently has a price-to-earnings ratio of 0. Navidea Biopharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, December 18th, 2024 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/14/2023 | Q3 2023 | -$0.02 | $0 | $0 | ||
08/11/2023 | Q2 2023 | $0.12 | $0 | |||
05/11/2023 | Q1 2023 | -$0.02 | $0 | |||
03/27/2023 | Q4 2022 | -$0.17 | $610 | |||
11/14/2022 | Q3 2022 | -$0.19 | $7,516 | |||
08/15/2022 | Q2 2022 | -$0.10 | $6,519 | |||
05/16/2022 | Q1 2022 | -$0.10 | $0 | |||
03/28/2022 | Q4 2021 | -$0.12 | $50,348 | |||
11/12/2021 | Q3 2021 | -$0.08 | $600,000 | $96,382 | ||
08/12/2021 | Q2 2021 | -$0.09 | $600,000 | $261,046 | ||
05/13/2021 | Q1 2021 | -$0.11 | $123,737 | |||
03/26/2021 | Q4 2020 | -$0.11 | $219,251 | |||
11/13/2020 | Q3 2020 | -$0.11 | $300,000 | $6,773 | ||
08/14/2020 | Q2 2020 | -$0.10 | $600,000 | $8,920 | ||
05/15/2020 | Q1 2020 | -$0.13 | $15,221 | |||
03/18/2020 | Q4 2019 | -$0.15 | $2,680 | |||
11/08/2019 | Q3 2019 | -$0.17 | $4,895 | |||
08/09/2019 | Q2 2019 | -$0.24 | $162,557 | $15,893 | ||
05/09/2019 | Q1 2019 | -$0.24 | $97,558 | |||
03/15/2019 | Q4 2018 | -$0.33 | $35,040 |
Navidea Biopharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, December 18th, 2024 based off last year's report dates.
The conference call for Navidea Biopharmaceuticals, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Navidea Biopharmaceuticals, Inc.'s latest earnings report can be read online.
Navidea Biopharmaceuticals, Inc. (:NAVB) has a recorded annual revenue of $65,652.
Navidea Biopharmaceuticals, Inc. (:NAVB) has a recorded net income of $65,652. Navidea Biopharmaceuticals, Inc. has generated $-0.59 earnings per share over the last four quarters.
Navidea Biopharmaceuticals, Inc. (:NAVB) has a price-to-earnings ratio of 0 and price/earnings-to-growth ratio is 0.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED